mRNA Cancer Vaccine Shows Promising Results in Melanoma Trial

A groundbreaking clinical trial has yielded promising results for an experimental mRNA cancer vaccine developed by pharmaceutical companies Merck and Moderna.

The Phase 3 trial, which included over 1,000 melanoma patients whose tumors had been removed but were at risk of their cancer returning, showed that the combination of intismeran, a personalized cancer vaccine, and Keytruda, a monoclonal antibody, was more effective than administering Keytruda alone.

The trial's primary goal was met, with an interim analysis indicating that the combination had minimal side effects, including fatigue and fever, while preventing the return and spread of melanoma in patients.

Catherine Wu, a physician and researcher at Harvard's Dana-Farber Cancer Institute, noted that the odds are good for this type of vaccine to work for other types of cancer as well.